To overcome this challenge, we tested the systemic delivery of a next-generation CDN-based STING agonist and compared its anti-tumor efficacy and elicited immune responses with the intratumoral (IT) injection of this agent (IT-STING) first in a mouse liver metastasis model [5] of pancreatic ductal adenocarcinoma (PDAC) to resemble IT and intramuscular (IM) injection of STING agonist in metastatic cancer patients (Fig.S1). Here, STING1 is linked to pancreatic ductal adenocarcinoma.